Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

⚠ Report — not peer-reviewed alzhub usefulness score 16 out of 100. Health systems and care delivery

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Accelerated approval of aducanumab for mild Alzheimer's by the U.S. Food and Drug Administration on June 7, 2021, has generated substantial medical, scientific, and ethical controversy. That approval was contrary to the nearly unanimous judgment of the FDA's Advisory Committee that little reliable evidence existed of significant benefit, even though the drug did reduce β-amyloid. Three major ethical problems were created by this approval: (1) Medicare resources would be unjustly squandered, given the drug's $56,000 annual price and the 3.1 million older potential American patients needing the drug; (2) physicians will feel ethically compelled to provide the drug to desperate, insistent patients, given FDA approval and in spite of side effects of brain bleeds and brain swelling; (3) and false hopes are generated for patients. A needed corrective by the federal government would reduce reimbursement to the bare cost of producing the drug (plus only a modest profit) until a phase IV trial has been successfully completed.

What this study adds

Evidence grade: Low

This article argues that aducanumab's accelerated approval was contrary to the FDA Advisory Committee's judgment that little reliable evidence existed of significant benefit, and it raises concerns about cost, side effects, and false hope. It is a commentary on approval and reimbursement, not new evidence that the drug treats or cures Alzheimer's disease.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Fleck Leonard, M. (2021). Alzheimer's and Aducanumab: Unjust Profits and False Hopes. The Hastings Center report. https://doi.org/10.1002/hast.1264

Vancouver

Fleck Leonard M. Alzheimer's and Aducanumab: Unjust Profits and False Hopes. The Hastings Center report. 2021. doi:10.1002/hast.1264. PMID: 34156732.

BibTeX

@article{fleckleonard2021-34156732,
  author  = {Fleck Leonard, M.},
  title   = {{Alzheimer's and Aducanumab: Unjust Profits and False Hopes}},
  journal = {The Hastings Center report},
  year    = {2021},
  doi     = {10.1002/hast.1264},
  pmid    = {34156732},
  url     = {https://doi.org/10.1002/hast.1264}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

This article argues that aducanumab's accelerated approval was contrary to the FDA Advisory Committee's judgment that little reliable evidence existed of significant benefit, and it raises concerns about cost, side effects, and false hope. It is a commentary on approval and reimbursement, not new evidence that the drug treats or cures Alzheimer's disease.

Study details

How this study scored 16/100
How this study's score is builtJournal tier 2 of 10; Journal's citation record 0 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 3 of 10; How recent 3 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 4 of 7; Citations per year 2 of 5; Impact for its field and year 3 of 6; Cited by studies here 0 of 6; Still being cited 2 of 4; Senior author's track record 2 of 4; Institution's track record left out, no data; Multicenter collaboration 0 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. 24 of the 97 points it could be judged on, which is 25 of 100. Raw total 25 of 100, shown as 16 because this is not a peer-reviewed research article.raw total 25 of 100capped at 16 — hatched points do not count

Report — not peer-reviewed. It scored 25 on the same rubric, but non-peer-reviewed sources are capped at 16, so it shows as 16. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on institution's track record, so that was left out: it earned 24 of the 97 points we could judge it on, which is 25 out of 100.

ComponentPointsWhy
Journal tier 2 / 10 Tier 4 — not a peer-reviewed journal (The Hastings Center report)
Journal's citation record 0 / 4 Not a journal article, so the journal's record does not count
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 3 / 10 Report — not peer-reviewed. Named source is an organizational report, not a journal article.
How recent 3 / 5 2021 — within 6 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 4 / 7 Cited 51 times (OpenAlex, 2026-10-10)
Citations per year 2 / 5 7.3 citations a year over 7 year(s) since 2021
Impact for its field and year 3 / 6 Cited 5.2× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 2 / 4 Cited 16 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Leonard Michael Fleck: h-index 20 (OpenAlex, whole career)
Institution's track record — / 3 No institution listed in OpenAlex — left out of this score
Multicenter collaboration 0 / 3 OpenAlex lists 0 institution(s) in 0 countries — scores zero (affiliation lists can be incomplete)
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 34156732)
Free to read 0 / 2 Behind a paywall — scores zero
Points 24 / 97 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 24 of the 97 points we could judge it on is 25 out of 100.
Total 25 / 100 Capped to 16 because this is not a peer-reviewed article.

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.

Studies in the library that share something with this one. The line above each title says what.

Related studies in Health systems and care delivery from nearby years

Also tagged “trial”

783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Health systems and care delivery

See all studies in Health systems and care delivery →